HEMATOLOGY

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.

Srikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.

During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.

In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.

Robert J. Soiffer, MD, discusses the approaches to integrating chimeric antigen receptor T-cell therapy into the treatment of hematologic malignancies.

VITAL study results reveal survival advantage of birtamimab for patients with Mayo Stage IV amyloid light chain amyloidosis.

Martin Dreyling, MD, discusses findings from the phase 3 TRIANGLE study of ibrutinib in patients with mantle cell lymphoma.

Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.

The SINTRA-REV trial showed lower risk of transfusion dependency in patients with MDS treated with lenalidomide.

COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.

Research conducted at Florida Cancer Specialists & Research Institute that is contributing to global advancements in the diagnosis and treatment of blood diseases will be presented at ASH 2022.

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.

Closing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.

Key opinion leaders provide a comprehensive review of agents under investigation, alone or in combination, in patients with myelofibrosis.

Shared insight on a number of novel therapies and treatment modalities being investigated in patients with blastic plasmacytoid dendritic cell neoplasm.

Focusing on real-world management of myelofibrosis, experts share insight on how they would select and sequence therapies within the current paradigm.

Comprehensive insight on the sequencing of agents in BPDCN management, followed by considerations for use of stem cell transplant in this setting.

A review of the treatment armamentarium for patients with myelofibrosis in the context of clinical trial data supporting use of these agents.

Shifting their attention to myelofibrosis, Rami S. Komrokji, MD, and Pankit Vachhani, MD, define differences between various subsets of disease.

Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.